Compare T-Rex 2X Long MSTR Daily Target ETF (MSTU) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
T-Rex 2X Long MSTR Daily Target ETF vs Travere Therapeutics Inc. Common Stock — how do they compare? T-Rex 2X Long MSTR Daily Target ETF trades at $32.75 (market cap $790.58M), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: Travere Therapeutics Inc. Common Stock is far larger — about 6.2× T-Rex 2X Long MSTR Daily Target ETF's market cap, and Travere Therapeutics Inc. Common Stock is trading nearer its 52-week high, T-Rex 2X Long MSTR Daily Target ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold T-Rex 2X Long MSTR Daily Target ETF for 19 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| MSTU | TVTX | |
|---|---|---|
Market Cap | $790.58M | $4.88B |
Volume | 1,852,380 | 1,668,577 |
Sector | Leveraged / Inverse | Health |
52-Week High | $389.00 | $67.52 |
52-Week Low | $14.60 | $26.79 |
Typical Hold Time | 19 Days | 0 Days |
Enterprise Value | — | $5.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MSTU trades at $38.54, down 0.57% with a bearish technical signal. The stock faces resistance at $40-$45 while finding support at $37-$33 levels. Recent corporate actions include a 10:1 reverse stock split effective August 24, 2026, and a $0.29 dividend declaration. Trading activity remains elevated as investors seek leveraged exposure to the underlying company amid market volatility.
The outlook remains cautious with technical indicators showing bearish momentum and limited fundamental data available. Key risks include the leveraged ETF structure's daily compounding effects and dependence on underlying stock performance. Investors should monitor for updated financial disclosures and analyst coverage to assess the fund's positioning and valuation metrics.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About T-Rex 2X Long MSTR Daily Target ETF
MSTU is a leveraged ETF that seeks daily investment results corresponding to 200% of the daily performance of the MicroStrategy Incorporated (MSTR) stock. It is designed as a tactical tool for experienced traders to take a bullish (long) position in MSTR, a company known for its significant Bitcoin holdings. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment.
Read more on MSTU →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
